What is Melanotan I?

Melanotan I is afamelanotide, a synthetic alpha-MSH analog and melanocortin agonist. Scenesse is a prescription subcutaneous implant for erythropoietic protoporphyria. [1][2][3]

Its high-confidence use is photoprotection in EPP, where increased eumelanin helps patients tolerate light exposure better. [1][2][3]

Melanotan I is distinct from Melanotan II. Afamelanotide has a regulated implant product and disease indication; Melanotan II is an unapproved tanning peptide with broader receptor activity. [1][2][3]

What Melanotan I is investigated for

Melanotan I evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

EPP photoprotection

Injectable

82% Strong

EPP photoprotection is the high-confidence Melanotan I/afamelanotide indication. [1][14][2]

Human evidence

FDA labeling and pivotal human trials support afamelanotide implant use for EPP photoprotection. [1][14][2]

Animal / mechanistic evidence

The photoprotective rationale follows alpha-MSH melanocortin activity and eumelanin induction. [1][14][2]

Vitiligo repigmentation with phototherapy

Injectable

58% Emerging

Vitiligo repigmentation is human-studied but separate from approved EPP photoprotection. [33]

Human evidence

A randomized multicenter trial evaluated afamelanotide with narrowband UV-B phototherapy for nonsegmental vitiligo. [33]

Animal / mechanistic evidence

The rationale is melanocortin-driven pigmentation combined with phototherapy-induced repigmentation. [33]

UV-free tanning and photoprotection

Injectable

56% Emerging

Pigmentation and tanning should be lower confidence than EPP and must not imply cosmetic approval. [4][7][3]

Human evidence

Human afamelanotide phototoxicity and photoprotection studies support pigmentation discussion, but cosmetic tanning is not the same as EPP treatment. [4][7][3]

Animal / mechanistic evidence

Melanocortin receptor activation supports eumelanin and photoprotection mechanisms. [4][7][3]

Acute stroke neuroprotection

Injectable

35% Preliminary

Acute stroke neuroprotection is human-studied at feasibility level, not an established stroke treatment. [18]

Human evidence

A small open-label feasibility and safety study evaluated afamelanotide in acute stroke patients; it was not definitive efficacy evidence. [18]

Animal / mechanistic evidence

The stroke rationale is melanocortin-related neuroprotection and vascular biology, separate from EPP photoprotection. [18]

Skin DNA-repair biology

Injectable

30% Limited

DNA-repair biology helps explain photoprotection interest, but it should not be written as proven skin-cancer prevention or cosmetic sunscreen replacement. [19][14]

Human evidence

Clinical photoprotection evidence exists for EPP, but DNA-repair enhancement itself is not established as a separate human clinical endpoint. [1][14]

Animal / mechanistic evidence

MC1R and alpha-MSH literature supports reduced UV-induced DNA damage and repair-pathway activation in skin models. [19][20]

Evidence snapshot

Overall confidence

Strong

82%

Afamelanotide has strong support for EPP photoprotection via an approved implant. Cosmetic tanning or Melanotan II-style use does not follow from that indication. [1][2][3]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

82%

Human evidence

Strong

FDA labeling and clinical trials support afamelanotide implant use for EPP photoprotection. [1][2][3]

34%

Animal / preclinical

Limited

MC1R-driven eumelanin production directly supports the photoprotection mechanism. [1][2][3]

82%

Mechanism support

Strong

Afamelanotide activates melanocortin-1 receptors on melanocytes, increasing eumelanin production. In EPP, that pigment response can improve photoprotection. [1][2][3]

Forms & administration

Melanotan I content separates approved afamelanotide implant labeling from unapproved tanning-peptide discussions. The approved form is an implant, not a self-injected tanning vial. [14][15][1]

Injectable

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

SCENESSE labeling uses a 16 mg afamelanotide implant. This implant range is separate from unapproved self-injected tanning protocols. [14][15][1]

Frequency

SCENESSE labeling uses one subcutaneous implant every 2 months. [14][15][1]

Timing Considerations

Timing is planned around EPP management and light-exposure risk, with sun and light protection maintained during treatment. [14][15][1]

Cycle Length

SCENESSE treatment follows a specialist-directed review window with ongoing skin monitoring and EPP outcome review. [14][15][1]

What to expect

First 2 months

Subcutaneous afamelanotide implant treatment gradually increases pigmentation and light tolerance in the EPP treatment context. [1][2][3][14][15]

Months 3-6

Subcutaneous implant outcomes center on phototoxic symptoms, pain-free light exposure, outdoor activity, and dermatology skin checks. [1][2][3][14][15]

After stopping

Pigmentation and photoprotection gradually fade after subcutaneous afamelanotide implants stop as exposure and skin turnover change. [1][2][3][14][15]

Safety profile

Melanotan I safety should separate SCENESSE implant labeling for EPP from non-label tanning use. Skin monitoring, implant-site reactions, nausea, fatigue, and pigmentation matter. [14][1]

Common side effects

Implant-site reactions [14][1]
Nausea [14][1]
Fatigue [14][1]
Dizziness [14][1]

Cautions

Skin monitoring [14][1]
Specialist implant use [14][1]
Non-label tanning [14][1]

What we don't know

Cosmetic tanning protocols and self-injected products are separate from the SCENESSE EPP label and have different safety uncertainty. [14][1]

Who Melanotan I is not for

Route-specific avoid and medical-review notes:

Use outside label without clinician oversight
Use outside label without clinician oversight warrants medical review or avoidance for Melanotan I. [14][1][2][3]
Concerning moles without dermatology review
Concerning moles without dermatology review warrants medical review or avoidance for Melanotan I. [14][1][2][3]
Pregnancy or breastfeeding unless specifically supervised
Pregnancy or breastfeeding unless specifically supervised warrants medical review or avoidance for Melanotan I. [14][1][2][3]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Photosensitizers / UV exposure
Photosensitizing drugs and intentional UV tanning can change burn, pigmentation, and skin-monitoring decisions; this is a route-specific caution. [14][1]
Melanocortin tanning products
Melanotan II, bremelanotide, or other melanocortin products can stack pigmentation, nausea, and vascular effects; this is a theoretical pathway caution. [14][1]
Immunosuppressants / skin risk
Immunosuppressants or therapies that raise skin-cancer risk can change dermatology monitoring decisions; this is a route-specific caution. [14][1]

Regulatory status

United States

In the U.S. as of 2026-06-21, SCENESSE afamelanotide is FDA-approved for erythropoietic protoporphyria photoprotection. Cosmetic tanning, self-injected Melanotan I, and compounded products are outside that approved implant program. [14][15][16][22]

Route	FDA drug approval	503A compounding
Injectable	Approved SCENESSE afamelanotide implant is FDA-approved for erythropoietic protoporphyria photoprotection; cosmetic tanning products or self-injected Melanotan I are separate. [14][15][15]	Not Listed 503A compounding for Melanotan I is separate from FDA-approved product labeling; a compounded preparation is not the approved product and is not FDA-approved. [14][15][15][16][22][23]

Injectable

FDA drug approval

Approved

SCENESSE afamelanotide implant is FDA-approved for erythropoietic protoporphyria photoprotection; cosmetic tanning products or self-injected Melanotan I are separate. [14][15][15]

503A compounding

Not Listed

503A compounding for Melanotan I is separate from FDA-approved product labeling; a compounded preparation is not the approved product and is not FDA-approved. [14][15][15][16][22][23]

International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. A U.S. FDA approval does not automatically establish the same approved indication, route, or product status in those markets. [25][26][27][28]

Sports & competition

WADA does not list Melanotan I here as S2 in the same way as GH or gonadotropins, but non-approved systemic, wellness, or compounded use can still require S0-style anti-doping review. [17][15][16][22][23]

How it works

Melanotan I, clinically developed as afamelanotide, activates melanocortin-1 receptors on melanocytes and increases eumelanin production. In plain terms, it darkens pigment in a way that can improve photoprotection for erythropoietic protoporphyria patients. [1][2][3]

Delivery and indication define the mechanism. The approved afamelanotide context uses an implant under medical supervision with phototoxic disease monitoring; that is not equivalent to casual tanning injections, research-market vials, or unsupervised pigment manipulation. The route, implant format, and disease context are what make the pharmacology clinically interpretable. [1][2][3]

Research gaps & open questions

What the current literature has not yet settled about Melanotan I:

A key evidence gap is non-EPP use evidence. [1][2][3]

A key evidence gap is long-term dermatology outcomes outside labeled care. [1][2][3]

A key evidence gap is clear public distinction from Melanotan II products. [1][2][3]

Common questions

Is Melanotan I FDA-approved?

Yes. Afamelanotide is FDA-approved as SCENESSE for EPP photoprotection; that is not approval for cosmetic tanning. [15][16][14][1]

Is Melanotan I the same as Melanotan II?

No. Afamelanotide has a disease-specific approved implant product; Melanotan II is an unapproved systemic tanning peptide. [15][16][14][1]

Is it approved for cosmetic tanning?

No. Melanotan I is not FDA-approved for cosmetic tanning; SCENESSE is approved for EPP photoprotection. [15][16][14][1]

Myths & misconceptions

Myth

Scenesse approval means melanotan is approved for tanning.

Reality

Approval is for EPP photoprotection, not cosmetic tanning. [1][2][3]

Myth

All melanotan peptides are interchangeable.

Reality

Receptor selectivity, route, evidence, and regulatory status differ. [1][2][3]

History & discovery

Melanotan I developed into afamelanotide, an alpha-MSH analog aimed at increasing eumelanin and photoprotection. Its history is disease-specific rather than a general tanning-product story. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty. [1][2][3][14]

Clinical studies in erythropoietic protoporphyria tested whether afamelanotide could increase pain-free light exposure. That established photoprotection as the main outcome, not cosmetic tanning. [1][2][3][14]

FDA approval of SCENESSE created a supervised implant precedent for adult EPP patients. The milestone narrowed the route and indication, separating afamelanotide from unapproved tanning injections. [1][2][3][14]

Published research 20 studies

[1]

Afamelanotide for Erythropoietic Protoporphyria.

N Engl J Med, 2015 Jul 2. human clinical.

[2]

Afamelanotide: A Review in Erythropoietic Protoporphyria.

Am J Clin Dermatol, 2016 Apr. review.

[3]

Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria.

Expert Rev Clin Pharmacol, 2021 Feb. review.

[4]

Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria.

Expert Rev Clin Pharmacol, 2015 Jan. review.

[5]

Vitamin D status in patients with erythropoietic protoporphyria taking the systemic photoprotective agent afamelanotide.

Br J Dermatol, 2024 Aug 14. human clinical.

[6]

Advances in the management of erythropoietic protoporphyria - role of afamelanotide.

Appl Clin Genet, 2016. review.

[7]

Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria.

Expert Opin Investig Drugs, 2010 Dec. review.

[8]

The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study.

Br J Dermatol, 2024 Aug 14. review.

[9]

German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria (EPP).

Photodermatol Photoimmunol Photomed, 2025 Mar. human clinical.

[10]

[Porphyrias-what is verified?].

Internist (Berl), 2018 Dec. review.

[11]

A bioassay for the detection of neutralizing antibodies against the α-melanocyte stimulating hormone analog afamelanotide in patients with erythropoietic protoporphyria.

J Pharm Biomed Anal, 2013 Mar 5. human clinical.

[12]

Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide - a three years observational study.

Orphanet J Rare Dis, 2020 Aug 18. human clinical.

[13]

Evaluation of the immunogenicity of the synthetic α-melanocyte-stimulating hormone (α-MSH) analogue afamelanotide ([Nle4-D-Phe7]-α-MSH, Scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-α-MSH antibodies.

Skin Pharmacol Physiol, 2015. human clinical.

[14]

SCENESSE afamelanotide implant prescribing information

U.S. Food and Drug Administration. official guidance.

[15]

Drugs@FDA/openFDA query for Melanotan I

U.S. Food and Drug Administration. database query.

[16]

Compounding and the FDA: Questions and Answers

U.S. Food and Drug Administration. official guidance.

[17]

The 2026 List of Prohibited Substances and Methods

World Anti-Doping Agency. regulatory.

[18]

A feasibility and safety study of afamelanotide in acute stroke patients.

PubMed, 2023. human clinical.

[19]

Significance of the melanocortin 1 receptor in the DNA damage response to ultraviolet radiation.

PubMed, 2014. review.

[20]

Alpha-melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage.

PubMed, 2005. in vitro.